Breaking News from ASCO's Annual Meeting — Physician’s First Watch

Medical News |
June 2, 2014

Breaking News from ASCO's Annual Meeting

By Kelly Young

Edited by Susan Sadoughi, MD , and Jaye Elizabeth Hefner, MD

The American Society of Clinical Oncology (ASCO) is holding its annual meeting in Chicago. Here are highlights from some of the phase 3 trials presented over the weekend:

In the PREVAIL trial, roughly 1700 men with metastatic prostate cancer who had received androgen-deprivation therapy but not chemotherapy were randomized to receive daily enzalutamide (an androgen-receptor antagonist) or placebo. At 12 months, radiographic progression-free survival was higher in the enzalutamide group (65% vs. 14%).

In TEXT and SOFT trials, roughly 4700 premenopausal women with hormone-receptor-positive early breast cancer were randomized to the aromatase inhibitor exemestane or tamoxifen. Both groups received ovarian suppression. At 5 years, disease-free survival was significantly higher in the exemestane group than the tamoxifen group (91.1% vs. 87.3%).

In the POEMS trial on preserving fertility, some 200 premenopausal women with hormone-receptor-negative breast cancer were randomized to receive chemotherapy with or without monthly injections of goserelin, a gonadotropin-releasing hormone agonist. The 2-year premature ovarian failure rate was lower in the goserelin arm (8% vs. 22%). In addition, more pregnancies occurred in the treatment group.

Reader Comments (4)


English is not my mother tongue. But The progression free survivak time with enzalutamide should be read as higher and not lower

GM, MD Physician, Oncology, France

Ok Prevail is a important clinical trial, but results are know since ASCO GU 2014. What about Docetaxel in Men with Newly Metastatic Prostate Cancer ?

Daniel Reiss, student Medical Student

I believe the PREVAIL results were actually an increase in radiographic disease-free survival, not "lower" as suggested in the summary (maybe a little typo?). The trial was stopped early because of strong results, wasn't it?


Is a good new for person with metastasis prostate cancer, because many patients (include me) I have bone metastasis with few action of the androgen deprivation with injection

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.